Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly ...

Interest in weight-loss medications is at an all-time high, with promising study results and inspiring success stories coming ...

SaveHealth explores what the research says about Ozempic's effects on insulin resistance and related conditions.

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by China-based The United Laboratories International Holdings Limited.

It’s not a miracle drug —an Ozempic user tells us that nutrition and extreme discipline are the only ways to make it work ...

This is when your doctor increases your Ozempic dosage. The typical starting dose of Ozempic is 0.25 mg once weekly. Over 4-week intervals, your doctor can gradually increase this to 2 mg once weekly.